Caladrius Biosciences to Participate in the 8th Annual Chief Medical Officer Summit 360°

BASKING RIDGE, N.J., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that its Chief Medical Officer, Douglas W. Losordo, M.D., FACC, FAHA, will participate in 8th annual Chief Medical Officer Summit 360°, being held virtually on October 26-27, 2020.

Follow this link:
Caladrius Biosciences to Participate in the 8th Annual Chief Medical Officer Summit 360°

Novan to Present at the Virtual Investor KOL Roundtable

- Live moderated video webcast discussion between members of management and Key Opinion Leader, John Browning, MD, FAAD, FAAP, MBA on Tuesday October 27th at 12:00 PM ET - Live moderated video webcast discussion between members of management and Key Opinion Leader, John Browning, MD, FAAD, FAAP, MBA on Tuesday October 27th at 12:00 PM ET

Read more from the original source:
Novan to Present at the Virtual Investor KOL Roundtable

Tauri-Gum Product Line Now Available at Select Mobil and Shell Gas Station Convenience Store Locations

Continue reading here:
Tauri-Gum Product Line Now Available at Select Mobil and Shell Gas Station Convenience Store Locations

Composition of the Nomination Committee of Orion Corporation

ORION CORPORATION     STOCK EXCHANGE RELEASE   21 OCTOBER 2020 at 6.40  p.m. EEST

Read the rest here:
Composition of the Nomination Committee of Orion Corporation

National Alliance reveals shocking truths about the world’s leading killer of women

OTTAWA, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Cardiovascular disease (CVD) is the country’s leading cause of premature death in women. The Canadian Women’s Heart Health Alliance (CWHHA), a national network of women’s heart health experts and advocates powered by the Canadian Women’s Heart Health Centre (CWHHC) at the University of Ottawa Heart Institute (UOHI), released eye-opening research this week revealing the scope of the problem.

Originally posted here:
National Alliance reveals shocking truths about the world’s leading killer of women

Theratechnologies Appoints Two New Board Members

MONTREAL, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Mr. Andrew Molson and Mr. Alain Trudeau as new independent members to its Board of Directors.

Follow this link:
Theratechnologies Appoints Two New Board Members

Nephros Announces Pricing of $5 Million Registered Direct Offering of Common Stock

SOUTH ORANGE, NJ, Oct. 16, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros, Inc. (Nasdaq: NEPH) (“Nephros” or the “Company”), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical device and commercial markets, today announced the pricing of a registered direct offering of 833,333 shares of common stock at a price to the public of $6.00 per share.  The offering is expected to close on or about October 20, 2020, subject to the satisfaction of customary closing conditions.

More:
Nephros Announces Pricing of $5 Million Registered Direct Offering of Common Stock

Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol

Originally posted here:
Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol

Aimmune Receives Positive CHMP Opinion on PALFORZIA® for the Treatment of Patients with Peanut Allergy in Europe

Final European Commission Decision on Marketing Approval Anticipated in Q4 2020 Final European Commission Decision on Marketing Approval Anticipated in Q4 2020

See the original post here:
Aimmune Receives Positive CHMP Opinion on PALFORZIA® for the Treatment of Patients with Peanut Allergy in Europe

CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis

CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis

See original here:
CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis